Lalor Angela S reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Angela S. Lalor received a stock grant of 9,346 shares of common stock on May 19, 2026. The award was recorded at a price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase. Following this grant, she directly holds 31,486 Enovis common shares.
PERFALL A CLAYTON reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director A. Clayton Perfall reported a stock grant and updated holdings. The filing shows a grant or award of 9,346 shares of common stock at no cash cost, bringing his directly held stake to 54,190 shares. A separate entry reports indirect ownership of 2,482 shares held by a trust.
The transactions are compensation and ownership updates rather than open-market buying or selling, so they mainly clarify the director’s equity position in Enovis.
Kelly Liam reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Liam Kelly received a grant of 9,346 shares of common stock. The award was reported at a price of $0.00 per share, indicating it was a compensation-related grant rather than an open-market purchase. Following this grant, Kelly directly holds a total of 28,950 Enovis common shares.
Wienbar Sharon L reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Sharon L. Wienbar received a grant of 9,346 shares of common stock on May 19, 2026. The shares were awarded at a stated price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase. Following this award, she directly holds 41,946 shares of Enovis common stock.
Vinnakota Rajiv reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Rajiv Vinnakota received a grant of 9,346 shares of common stock on May 19, 2026 at no cost as an equity award. This increased his directly held stake to 37,608 shares. The transaction reflects routine stock-based compensation, not an open-market purchase or sale.
Enovis Corporation reported the results of its Annual Meeting held on May 19, 2026. Stockholders approved an amendment to the 2020 Omnibus Incentive Plan that authorizes an additional 3,650,000 shares of common stock for equity awards and raises the annual compensation cap for each Outside Director from $350,000 to $750,000, with up to 200% of that limit allowed in certain first-year or leadership appointment situations.
All ten director nominees were elected, each receiving over 50 million votes in favor with relatively few votes against. Stockholders ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers. The plan amendment will be implemented through a Form S-8 registration of the additional shares.
Enovis CORP Chief Executive Officer Damien McDonald reported a routine tax-related share disposition. On May 12, 2026, 12,634 shares of common stock at $25.99 per share were withheld by the company to satisfy tax obligations tied to net-settled restricted stock units, and this was not an open-market sale. After this withholding, McDonald directly holds 234,042 shares of Enovis common stock.
Enovis CORP SVP and Chief Financial Officer Phillip Ben Berry reported a tax-related share withholding, not an open-market sale. On this Form 4, 7,774 shares of common stock were withheld by the company at $25.99 per share to satisfy tax obligations tied to restricted stock units. After this withholding, Berry directly holds 150,822 shares of Enovis common stock.
Enovis Corporation reported higher sales and a much smaller loss for the three months ended April 3, 2026. Net sales rose to $589.2 million from $558.8 million, led by growth in the Reconstructive segment and modest gains in Prevention & Recovery.
Gross profit increased to $365.5 million, lifting gross margin to 62.0% from 59.4% as product mix and lower inventory step-up charges helped profitability. Net loss narrowed to $8.5 million, or $0.15 per share, compared with a $55.7 million loss a year earlier, helped by the absence of a prior one-time royalty buyout expense.
Adjusted EBITDA, a key non-GAAP metric, improved to $103.6 million from $87.1 million, with margins rising to 17.6%. Cash flow from operating activities turned positive at $24.0 million versus a slight outflow in the prior year, while the company ended the quarter with $33.1 million in cash and total debt of $1.33 billion.
Enovis Corporation reported higher first-quarter 2026 sales while remaining loss-making on a GAAP basis but stronger on adjusted metrics. Net sales were $589.2 million, up 5.4% year over year and 3.3% organically, driven by 10.8% reported growth in Reconstructive, while Prevention & Recovery was flat.
The company posted a GAAP net loss of $8.5 million, a net margin of (1.4)%, but generated adjusted net income from continuing operations of $51.6 million, or $0.89 per diluted share, up from $0.65 a year earlier. Adjusted EBITDA was $103.6 million, representing a 17.6% margin versus 15.6% last year.
Enovis reaffirmed its full-year 2026 outlook, expecting revenue of about $2.31–$2.37 billion, incorporating 4–6% organic growth, adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and free cash flow conversion of 25% or higher.